COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Updates Comparative Performance Data to Include Most Available SARS-CoV-2 Diagnostic Tests

FDA maze of regulations
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

New FDA update to comparative COVID-19 test performance data now includes information about most available SARS-CoV-2 diagnostic molecular tests

The US Food and Drug Administration (FDA) provided a SARS-CoV-2 reference panel for test developers in late May 2020. The purpose of this panel was for test developers and manufacturers to use it while developing and validating tests. Another purpose of the panel was to allow for the comparison of the performance of each COVID-19 diagnostic test alongside others.

The FDA released partial data on various COVID-19 diagnostic tests’ relative performance using this panel in mid-September 2020, but several tests were not included at the time as the FDA was still compiling data. However, on Sept. 20, the FDA announced an update to this data, including information on approximately 165 diagnostic tests.

While some of the SARS-CoV-2 molecular diagnostic tests did not provide data, or provided data that is under review, the FDA has made public the relative limit of detection of approximately 83 tests and has divided the data into three categories:

  1. swabs in transport media,
  2. direct swabs (dry swabs), and
  3. saliva.

The FDA’s comparative update represents data or the status of this data on most of the SARS-CoV-2 diagnostic tests that are commercially available in the United States. The FDA has announced the intention to update comparative COVID-19 test performance data frequently (see the most current comparative data), allowing clinical laboratory leaders insights into how each test performs.

Related Resources:

FDA: SARS-CoV-2 Reference Panel Comparative Data

FDA: Coronavirus (COVID-19) Update: Daily Roundup September 30, 2020


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group